DJDavid. M. Janicke

David. M. Janicke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David. M. Janicke has a total of 212 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents

    by Matthew F. Daley, Sheryl L. Rifas‐Shiman, Jessica G. Young, Joshua Petimar, Carly Prentice, L. Charles Bailey, David M. Janicke, William J. Heerman, Jason P. Block

    Background: Antihypertensive class medications are prescribed long‐term for adolescents, including for conditions other than hypertension. Evidence on weight effects is limited. Objective: To assess the weight effects of commonly prescribed antihypertensive class medications among adolescents, regardless of clinical indication for use. Methods: This retrospective study was conducted using electronic health record (EHR) data from a multi‐site US research network. The study cohort included adolescents aged 13.0–19.5 years with ≥ 1 antihypertensive class medication order during 2010–2019. Weight and height documented in the EHR were used to calculate BMI z‐scores. Inverse probability weighting with marginal structural models was used to account for selection factors and covariates. Results: Overall, 23 853 adolescents were prescribed an antihypertensive class medication, including clonidine (prescribed to n = 7491), guanfacine ( n = 6411), lisinopril ( n = 3584), propranolol ( n = 3015), spironolactone ( n = 1926), and atenolol ( n = 1426). At baseline, 13% had a hypertension diagnosis. At 12 months after medication initiation, the estimated population‐level BMI z‐score was significantly increased for propranolol (BMI z‐score 0.19 [95% CI 0.09, 0.29]) and significantly decreased for lisinopril (−0.06 [95% CI −0.10, −0.01]); clonidine, guanfacine, spironolactone, and atenolol were not associated with a significant change in BMI z‐score. Conclusions: Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.

  • Open Access

    Development and Usability Testing of the Mobile Childhood Asthma Management Program (mCHAMP) App: Sequential Mixed Methods Study

    by Robert J Lucero, Kristen Shear, Andrea Fidler, David Fedele, Yunpeng Xia, David Janicke

    Background: More than 6 million children in the United States have asthma, and more than 20% are clinically obese. Youth with asthma and obesity are susceptible to poor health outcomes, including greater asthma symptom severity and hospitalizations, reduced physical activity, and poorer quality of life. Mobile health technologies can increase access to chronic disease self-management interventions, and family members can be powerful influencers given their substantial control over a child’s behavior and home environment. Objective: The Mobile Childhood Asthma Management Program (mCHAMP) app is based on the in-person Childhood Asthma Management Program (CHAMP) behavioral family intervention pilot trial of school-aged children with asthma and obesity. In this study, we translated the CHAMP content into digital content and conducted summative testing to measure the usability, learnability, and efficiency of the mCHAMP app. Methods: We applied a sequential mixed methods approach. The mCHAMP app targeted adult caregivers of children living with asthma and obesity aged 6 to 12 years. A consumer-centered approach was used to guide the identification of user requirements and conduct of summative usability testing. While the mCHAMP app is primarily caregiver facing, it is intended to connect caregivers with registered nurse (RN) interventionists. Therefore, we sought feedback from RNs as key stakeholders. Results: Caregivers (n=10) were female (n=10, 100%) and mostly African American (n=8, 80%), and half (n=5, 50%) had an annual household income of <US $25,000; most of their children (n=6, 60%) were in the 99th BMI percentile. Post-Study eHealth Usability Questionnaire scores indicated high overall satisfaction, usefulness, and quality of the mCHAMP app. Most caregivers (n=7, 70%) were able to complete all 15 tasks across the 6 modules with 2 or fewer hints. The average total time to complete all tasks was 17 (SD 3.9; range 11.4-24.1) minutes. Most caregivers (n=7, 70%) wanted information in static form but also preferred alternatives (eg, audio or video) to support flexibility with consuming the content. Caregivers expressed the need for more child-facing content as well as tailored decision support related to diet and exercise. RNs (n=5) strongly endorsed their role and use of the mCHAMP app to promote self-management among caregivers of children with obesity and asthma. They noted the importance of integrating the mCHAMP app into a local electronic health record and existing workflows. Conclusions: Caregivers expressed a desire for an intervention that was easy to use and could integrate into their busy family lives. We met this expectation based on the usability, learnability, and efficiency results of our study. The mCHAMP app has the potential to increase self-management for parents and pediatric patients with asthma with multimorbidity, which could improve patient and health system outcomes. The use of mCHAMP may also enable novel clinical outcome studies based on patient-reported data from the app. International Registered Report Identifier (IRRID): RR2-10.2196/13549


  • Comparative BMI-z Changes With Initiation and Adherence to Antidepressant Medications Among Youth

    by Sheryl L. Rifas-Shiman, Jessica G. Young, Han Yu, Matthew F. Daley, William J. Heerman, David M. Janicke, W. Schuyler Jones, Kristina H. Lewis, Pi-I.D. Lin, Carly Prentice, et al.


  • Open Access

    Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes

    by Nadia M. Sneed, Sheryl L. Rifas‐Shiman, Joshua Petimar, Jessica G. Young, L. Charles Bailey, Matthew F. Daley, David M. Janicke, W. Schuyler Jones, Carly Prentice, Jason P. Block, et al.

    Objective: This study aimed to estimate population‐level effects on weight change of initiating/adhering to additional glucose‐lowering medications in adults with type 2 diabetes prescribed metformin. Methods: We conducted a target trial using electronic health record data from 22,601 patients (age 20 to < 80 years) prescribed metformin to determine initiation/adherence to dipeptidyl peptidase IV (DPP4) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors, long‐acting insulin, or sulfonylureas. Inverse probability weighting of marginal structural models with standardization by baseline covariates was used to estimate population‐level effects of initiating/adhering to different medications on average 24‐month weight change. Results: At 24 months, a mean −5.15 kg (95% CI −10.6, −1.36) and −6.71 kg (95% CI −8.38, −4.34) weight loss would be observed for initiation/adherence to GLP‐1RAs and SGLT‐2s respectively. At 6 months, weight loss for DPP4s would be observed (−0.89 kg, 95% CI −1.41, −0.32) though not at 12 or 24 months. Glimepiride would be associated with weight gain at 6 and 12 months (0.88 kg, 95% CI 0.44, 1.22; 1.01 kg, 95% CI 0.32, 1.51) but not at 24 months. Conclusions: Initiation/adherence to GLP‐1RAs and SGLT‐2s over 24 months could result in average weight losses of 5.15 kg and 6.71 kg, respectively.


  • Long‐Term Medication‐Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study

    by Han Yu, Jessica G. Young, Joshua Petimar, Sheryl L. Rifas‐Shiman, Matthew F. Daley, William J. Heerman, David M. Janicke, W. Schuyler Jones, Takuya Kawahara, Kristina H. Lewis, et al.

    Objective: To estimate long‐term weight change after initiation and adherence to commonly used antiseizure medications (ASMs) and examine differences in weight change across ASMs compared to topiramate. Methods: We included 52,309 adult patients who initiated ASMs, applied a target trial emulation approach to control time‐varying confounding and selection bias, and examined the long‐term comparative effects on weight change after initiating and adhering to different ASMs at 6 and 12 months post initiation. Results: The most commonly initiated ASM was topiramate (41.2%). In comparison to topiramate, we estimated higher 6‐month weight change under initiation and adherence to levetiracetam 0.94 kg (95% CI 0.20, 1.64), lamotrigine 1.44 kg (0.74, 1.99), valproate 2.42 kg (1.71, 2.88), carbamazepine 1.32 kg (0.46, 2.16), and oxcarbazepine 1.74 kg (0.85, 2.71), with similar results at 12 months and in sensitivity and subgroup analyses. These results were driven mostly by weight loss with use of topiramate rather than weight gain with use of other ASMs. Results were similar though attenuated when accounting for medication initiation only. Conclusions: Topiramate was associated with weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation‐only effects; other medications were associated with higher weight change. These results provided important information to help with decision‐making regarding ASM initiation.


  • Open Access

    Development and Usability Testing of the Mobile Childhood Asthma Management Program (mCHAMP) App: Sequential Mixed Methods Study (Preprint)

    by Robert J Lucero, Kristen Shear, Andrea Fidler, David Fedele, Yunpeng Xia, David Janicke

    BACKGROUND More than 6 million children in the United States have asthma, and more than 20% are clinically obese. Youth with asthma and obesity are susceptible to poor health outcomes, including greater asthma symptom severity and hospitalizations, reduced physical activity, and poorer quality of life. Mobile health technologies can increase access to chronic disease self-management interventions, and family members can be powerful influencers given their substantial control over a child’s behavior and home environment. OBJECTIVE The Mobile Childhood Asthma Management Program (mCHAMP) app is based on the in-person Childhood Asthma Management Program (CHAMP) behavioral family intervention pilot trial of school-aged children with asthma and obesity. In this study, we translated the CHAMP content into digital content and conducted summative testing to measure the usability, learnability, and efficiency of the mCHAMP app. METHODS We applied a sequential mixed methods approach. The mCHAMP app targeted adult caregivers of children living with asthma and obesity aged 6 to 12 years. A consumer-centered approach was used to guide the identification of user requirements and conduct of summative usability testing. While the mCHAMP app is primarily caregiver facing, it is intended to connect caregivers with registered nurse (RN) interventionists. Therefore, we sought feedback from RNs as key stakeholders. RESULTS Caregivers (n=10) were female (n=10, 100%) and mostly African American (n=8, 80%), and half (n=5, 50%) had an annual household income of <US $25,000; most of their children (n=6, 60%) were in the 99th BMI percentile. Post-Study eHealth Usability Questionnaire scores indicated high overall satisfaction, usefulness, and quality of the mCHAMP app. Most caregivers (n=7, 70%) were able to complete all 15 tasks across the 6 modules with 2 or fewer hints. The average total time to complete all tasks was 17 (SD 3.9; range 11.4-24.1) minutes. Most caregivers (n=7, 70%) wanted information in static form but also preferred alternatives (eg, audio or video) to support flexibility with consuming the content. Caregivers expressed the need for more child-facing content as well as tailored decision support related to diet and exercise. RNs (n=5) strongly endorsed their role and use of the mCHAMP app to promote self-management among caregivers of children with obesity and asthma. They noted the importance of integrating the mCHAMP app into a local electronic health record and existing workflows. CONCLUSIONS Caregivers expressed a desire for an intervention that was easy to use and could integrate into their busy family lives. We met this expectation based on the usability, learnability, and efficiency results of our study. The mCHAMP app has the potential to increase self-management for parents and pediatric patients with asthma with multimorbidity, which could improve patient and health system outcomes. The use of mCHAMP may also enable novel clinical outcome studies based on patient-reported data from the app. INTERNATIONAL REGISTERED REPORT RR2-10.2196/13549

  • Medication-Induced Weight Change Across Common Antidepressant Treatments

    by Joshua Petimar, Jessica G. Young, Han Yu, Sheryl L. Rifas-Shiman, Matthew F. Daley, William J. Heerman, David M. Janicke, W. Schuyler Jones, Kristina H. Lewis, Pi-I D. Lin, et al.

    Antidepressants are among the most commonly prescribed medications, but evidence on comparative weight change for specific first-line treatments is limited. To compare weight change across common first-line antidepressant treatments by emulating a target trial. Observational cohort study over 24 months. Electronic health record (EHR) data from 2010 to 2019 across 8 U.S. health systems. 183 118 patients. Prescription data determined initiation of treatment with sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, or venlafaxine. The investigators estimated the population-level effects of initiating each treatment, relative to sertraline, on mean weight change (primary) and the probability of gaining at least 5% of baseline weight (secondary) 6 months after initiation. Inverse probability weighting of repeated outcome marginal structural models was used to account for baseline confounding and informative outcome measurement. In secondary analyses, the effects of initiating and adhering to each treatment protocol were estimated. Compared with that for sertraline, estimated 6-month weight gain was higher for escitalopram (difference, 0.41 kg [95% CI, 0.31 to 0.52 kg]), paroxetine (difference, 0.37 kg [CI, 0.20 to 0.54 kg]), duloxetine (difference, 0.34 kg [CI, 0.22 to 0.44 kg]), venlafaxine (difference, 0.17 kg [CI, 0.03 to 0.31 kg]), and citalopram (difference, 0.12 kg [CI, 0.02 to 0.23 kg]); similar for fluoxetine (difference, -0.07 kg [CI, -0.19 to 0.04 kg]); and lower for bupropion (difference, -0.22 kg [CI, -0.33 to -0.12 kg]). Escitalopram, paroxetine, and duloxetine were associated with 10% to 15% higher risk for gaining at least 5% of baseline weight, whereas bupropion was associated with 15% reduced risk. When the effects of initiation and adherence were estimated, associations were stronger but had wider CIs. Six-month adherence ranged from 28% (duloxetine) to 41% (bupropion). No data on medication dispensing, low medication adherence, incomplete data on adherence, and incomplete data on weight measures across time points. Small differences in mean weight change were found between 8 first-line antidepressants, with bupropion consistently showing the least weight gain, although adherence to medications over follow-up was low. Clinicians could consider potential weight gain when initiating antidepressant treatment. National Institutes of Health.


  • Open Access

    Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records

    by Pi‐I Debby Lin, Sheryl Rifas‐Shiman, John Merriman, Joshua Petimar, Han Yu, Matthew F. Daley, David M. Janicke, William J. Heerman, L. Charles Bailey, Carlos Maeztu, et al.

    Background: Guidelines for the use of antihypertensives changed in 2014 and 2017. To understand the effect of these guidelines, we examined trends in antihypertensive prescriptions in the United States from 2010 to 2019 using a repeated cross‐sectional design. Methods and Results: Using electronic health records from 15 health care institutions for adults (20–85 years old) who had ≥1 antihypertensive prescription, we assessed whether (1) prescriptions of beta blockers decreased after the 2014 Eighth Joint National Committee (JNC 8) report discouraged use for first‐line treatment, (2) prescriptions for calcium channel blockers and thiazide diuretics increased among Black patients after the JNC 8 report encouraged use as first‐line therapy, and (3) prescriptions for dual therapy and fixed‐dose combination among patients with blood pressure ≥140/90 mm Hg increased after recommendations in the 2017 Hypertension Clinical Practice Guidelines. The study included 1 074 314 patients with 2 133 158 prescription episodes. After publication of the JNC 8 report, prescriptions for beta blockers decreased (3% lower in 2018–2019 compared to 2010–2014), and calcium channel blockers increased among Black patients (20% higher in 2015–2017 and 41% higher in 2018–2019, compared to 2010–2014), in accordance with guideline recommendations. However, contrary to guidelines, dual therapy and fixed‐dose combination decreased after publication of the 2017 Hypertension Clinical Practice Guidelines (9% and 11% decrease in 2018–2019 for dual therapy and fixed‐dose combination, respectively, compared to 2015–2017), and thiazide diuretics decreased among Black patients after the JNC 8 report (6% lower in 2018–2019 compared to 2010–2014). Conclusions: Adherence to guidelines on prescribing antihypertensive medication was inconsistent, presenting an opportunity for interventions to achieve better blood pressure control in the US population.


  • Changes in obesity and BMI among children and adolescents with selected chronic conditions during the COVID‐19 pandemic

    by Sheryl L. Rifas‐Shiman, Izzuddin M. Aris, Charles Bailey, Matthew F. Daley, William J. Heerman, David M. Janicke, Pi‐I Debby Lin, Joshua Petimar, Jason P. Block

    Objective: The aim of this study was to examine COVID‐19 pandemic‐related changes in obesity and BMI among patients aged 5 to z score during the pandemic (June through December 2020) versus pre‐pandemic (June through December 2019).Results: Obesity prevalence increased from 23.8% before the pandemic to 25.5% during the pandemic; mean (SD) BMI z score increased from 0.62 (1.26) to 0.65 (1.29). Obesity prevalence during the pandemic increased at a faster rate compared with pre‐pandemic among children aged 5 to <13 years (0.27% per month; 95% CI: 0.11%‐0.44%) and 13 to <18 years (0.24% per month; 95% CI: 0.09%‐0.40%), with the largest increases among children aged 5 to <13 years who were male (0.42% per month), Black (0.35% per month), or Hispanic (0.59% per month) or who were prescribed antihypertensives (0.28% per month).Conclusions: The COVID‐19 pandemic has exacerbated the obesity epidemic and widened disparities among children with selected chronic conditions. These findings highlight the importance of continuing efforts to specifically help high‐risk populations who are experiencing weight gain from the pandemic.


  • Open Access

    Antibiotics prior to age 2 years have limited association with preschool growth trajectory

    by L. Charles Bailey, Matthew Bryan, Mitchell Maltenfort, Jason P. Block, Rachel Teneralli, Douglas Lunsford, Janne Boone-Heinonen, Ihuoma Eneli, Casie E. Horgan, Pi-I D. Lin, et al.

    Background Prior studies of early antibiotic use and growth have shown mixed results, primarily on cross-sectional outcomes. This study examined the effect of oral antibiotics before age 24 months on growth trajectory at age 2–5 years. Methods We captured oral antibiotic prescriptions and anthropometrics from electronic health records through PCORnet, for children with ≥1 height and weight at 0–12 months of age, ≥1 at 12–30 months, and ≥2 between 25 and 72 months. Prescriptions were grouped into episodes by time and by antimicrobial spectrum. Longitudinal rate regression was used to assess differences in growth rate from 25 to 72 months of age. Models were adjusted for sex, race/ethnicity, steroid use, diagnosed asthma, complex chronic conditions, and infections. Results 430,376 children from 29 health U.S. systems were included, with 58% receiving antibiotics before 24 months. Exposure to any antibiotic was associated with an average 0.7% (95% CI 0.5, 0.9, p < 0.0001) greater rate of weight gain, corresponding to 0.05 kg additional weight. The estimated effect was slightly greater for narrow-spectrum (0.8% [0.6, 1.1]) than broad-spectrum (0.6% [0.3, 0.8], p < 0.0001) drugs. There was a small dose response relationship between the number of antibiotic episodes and weight gain. Conclusion Oral antibiotic use prior to 24 months of age was associated with very small changes in average growth rate at ages 2–5 years. The small effect size is unlikely to affect individual prescribing decisions, though it may reflect a biologic effect that can combine with others.